NCT02016872Completed
Prognostic Value of Tumor Hypoxia, as Measured by 18F-FMISO Breath Hold PET/CT, in Non-Small-Cell-Lung Cancer (NSCLC) Patients
Source: ClinicalTrials.gov · Last updated 30 Apr 2025
Brief summary (registry, in English)
The purpose of this study is to help researchers investigate if a new imaging agent named 18F-FMISO can predict if patients with lung cancer will respond to standard therapy, as well as whether disease will reoccur in the future. The study will also investigate whether a 18F-FDG PET scan in the middle of radiation treatment can predict if lung cancer will respond to standard therapy. Information obtained from this study may help doctors design future studies in which they may target tumor areas that do not respond to therapy or may likely reoccur in the future.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 25 (actual)
- First submitted
- 16 Dec 2013
- Start date
- Dec 2013
- Primary completion date
- Jul 2024
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Diseases
- Lung cancer
- NCT number
- NCT02016872
What you commit to
- Study type: Interventional
- Participants enrolled: 25
- From Dec 2013 to the primary completion date, Jul 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- Severe diabetes (fasting Blood Glucose \> 200 mg/dl)
Other
- Women who are pregnant or breast-feeding
Who the study is looking for
- Pathologic confirmation of NSCLC at MSKCC
- No prior treatment for this diagnosis of NSCLC
- Patient to be treated with neoadjuvant chemotherapy (35 patients total) or patient to be treated with definitive RT,sequential chemo-RT, or concurrent chemo-RT (minimum dose of 50 Gy in 25 fractions) (25 patients total)
- Tumor must measure ≥ 2cm on CT
- Age ≥ 18 years
- Ability to hold the breath for 10 seconds.
- Karnofsky performance status ≥ 70%
- Women of childbearing age must have a negative blood pregnancy test
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Memorial Sloan-Kettering Cancer Center Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.